In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program | Zendy

Sandra P. McCurdy | Zendy; Ronald N. Jones | Zendy; Rodrigo E. Mendes | Zendy; Sailaja Puttagunta | Zendy; Michael W. Dunne | Zendy

Open Access

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

Author(s) -

Sandra P. McCurdy,

Ronald N. Jones,

Rodrigo E. Mendes,

Sailaja Puttagunta,

Michael W. Dunne

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00274-15

Subject(s) - dalbavancin , tigecycline , daptomycin , staphylococcus aureus , linezolid , microbiology and biotechnology , methicillin resistant staphylococcus aureus , drug resistance , biology , antibiotics , virology , medicine , vancomycin , bacteria , genetics

In over a decade (2002 to 2012) of Staphylococcus aureus surveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline. Nearly all (99.8%) multidrug-resistant methicillin-resistant S. aureus isolates were inhibited by dalbavancin at ≤0.12 μg/ml (MIC50/90, 0.06/0.06 μg/ml), the current U.S. Food and Drug Administration (U.S. FDA) breakpoint. Overall, only 0.35% of the monitored S. aureus isolates had a dalbavancin MIC of either 0.25 or 0.5 μg/ml (i.e., were nonsusceptible).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research